FLGT * Stock Overview Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Fulgent Genetics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Fulgent Genetics Historical stock prices Current Share Price US$380.00 52 Week High US$459.00 52 Week Low US$345.01 Beta 1.41 1 Month Change 6.15% 3 Month Change -10.59% 1 Year Change n/a 3 Year Change -80.97% 5 Year Change n/a Change since IPO -60.00%
Recent News & Updates
Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023) Nov 09
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024 Nov 08
New minor risk - Shareholder dilution Nov 03
Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 18
Chief Financial Officer recently sold Mex$729k worth of stock Sep 07
Chairman & CEO recently sold Mex$1.0m worth of stock Sep 01 See more updates
Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023) Nov 09
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024 Nov 08
New minor risk - Shareholder dilution Nov 03
Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 18
Chief Financial Officer recently sold Mex$729k worth of stock Sep 07
Chairman & CEO recently sold Mex$1.0m worth of stock Sep 01
Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023) Aug 03
Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024 Aug 02
Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024 Jul 12
First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023) May 05
Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 12
Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024 Mar 28
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022) Feb 29
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 14
Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022) Nov 04 Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting
Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023 Oct 18
Chief Financial Officer recently sold Mex$5.8m worth of stock Sep 01
Chief Financial Officer recently sold Mex$1.0m worth of stock Aug 23
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023 Aug 05
Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers Jun 07
COO & President recently sold Mex$824k worth of stock May 23
First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022) May 09
Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023 May 06
Less than half of directors are independent Mar 24
Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors Jan 04
Less than half of directors are independent Jan 04
COO & President recently sold Mex$457k worth of stock Dec 08
Less than half of directors are independent Dec 08 Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023
Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million. Nov 09
Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022 Nov 08
Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee Nov 05
The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc Oct 26
Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 21
Less than half of directors are independent Oct 07
Less than half of directors are independent Oct 04
Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board Sep 30
Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc Sep 21
Chief Financial Officer recently sold Mex$552k worth of stock Sep 10
COO & President recently sold Mex$599k worth of stock Sep 03
Investor sentiment deteriorated over the past week Sep 02
Chief Financial Officer recently sold Mex$1.9m worth of stock Aug 21
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022 Aug 06
Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021) Aug 05 Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox
Investor sentiment improved over the past week Jul 25
Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 20
Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test Jul 06
COO & President recently sold Mex$719k worth of stock Jun 09
COO & President recently sold Mex$719k worth of stock Jun 04
Chief Financial Officer recently sold Mex$1.3m worth of stock May 19
First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021) May 10 Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022
Fulgent Genetics, Inc. Announces Executive Appointments May 04 Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022
Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022 Mar 31
Chief Financial Officer recently sold Mex$530k worth of stock Mar 09
Chief Financial Officer recently sold Mex$530k worth of stock Mar 06
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 25
Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022 Feb 24
Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 15
Investor sentiment deteriorated over the past week Jan 06
Chief Financial Officer recently sold Mex$1.1m worth of stock Dec 10
Investor sentiment deteriorated over the past week Dec 09
Chief Operating Officer recently sold Mex$1.3m worth of stock Dec 03
Chief Operating Officer recently sold Mex$2.4m worth of stock Nov 20
Investor sentiment improved over the past week Nov 19
Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020) Nov 11
Chief Financial Officer recently sold Mex$1.1m worth of stock Sep 10
Chief Operating Officer recently sold Mex$1.1m worth of stock Sep 02
Chief Operating Officer recently sold Mex$2.3m worth of stock Aug 19
Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020) Aug 11 Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.
Investor sentiment improved over the past week Aug 07
Investor sentiment improved over the past week Jul 24 Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 3000E Index
Investor sentiment improved over the past week Jun 24
Chief Financial Officer recently sold Mex$1.8m worth of stock Jun 09
Investor sentiment improved over the past week Jun 09
Chief Operating Officer recently sold Mex$2.8m worth of stock May 22
First quarter 2021 earnings released: EPS US$6.96 (vs US$0.091 loss in 1Q 2020) May 08
Fulgent Genetics, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021 May 07
Fulgent Genetics, Inc. Announces Award of Contract from CDC to Study Variants of COVID-19 Virus Mar 17
Chief Operating Officer recently sold Mex$135m worth of stock Mar 13
Full year 2020 earnings released: EPS US$9.44 (vs US$0.022 loss in FY 2019) Mar 06
Revenue beats expectations Mar 06 Shareholder Returns FLGT * MX Healthcare MX Market 7D 0% 1.5% -0.2% 1Y n/a -31.2% -14.8%
See full shareholder returns
Return vs Market: Insufficient data to determine how FLGT * performed against the MX Market .
Price Volatility Is FLGT *'s price volatile compared to industry and market? FLGT * volatility FLGT * Average Weekly Movement n/a Healthcare Industry Average Movement 6.6% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.7%
Stable Share Price: FLGT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine FLGT *'s volatility change over the past year.
About the Company Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Show more Fulgent Genetics, Inc. Fundamentals Summary How do Fulgent Genetics's earnings and revenue compare to its market cap? FLGT * fundamental statistics Market cap Mex$11.42b Earnings (TTM ) -Mex$3.33b Revenue (TTM ) Mex$5.60b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) FLGT * income statement (TTM ) Revenue US$277.76m Cost of Revenue US$177.17m Gross Profit US$100.60m Other Expenses US$265.56m Earnings -US$164.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.39 Gross Margin 36.22% Net Profit Margin -59.39% Debt/Equity Ratio 0.3%
How did FLGT * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 12:52 End of Day Share Price 2024/12/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Fulgent Genetics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Karen Koski BTIG Andrew Cooper CGS International Erin Wilson Wright Credit Suisse
Show 3 more analysts 
